Sunita D. Nasta

University of Pennsylvania — United States

Medicine · Health Sciences

40h-index9.8kcitations366works5.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(211), CAR-T cell therapy research(118), Chronic Lymphocytic Leukemia Research(100), Viral-associated cancers and disorders(43), CNS Lymphoma Diagnosis and Treatment(36)

Publications366 total

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study
Blood Advances·2026Open Access
Cardiovascular outcomes of patients transitioned from ibrutinib to an alternate bruton tyrosine kinase inhibitor for hypertension and/or cardiovascular adverse events
Blood·2025
Outcomes of patients with dual primary T-cell and B-cell lymphoid malignancies
Blood·2025Open Access
Outcomes in octo- and nonagenarians treated with mogamulizumab-based regimens for cutaneous T-cell lymphoma
Blood·2025
Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience
Blood·2025
Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies
Blood·2025
Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden
Blood·2025Open Access
Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease
Blood·2025Open Access
Risk factors for failure to complete step-up-dosing of bispecific antibody therapy for B-cell lymphomas
Blood·2025Open Access
Identification and functional characterization of a novel best-in-class anti-CD79b CAR T cell immunotherapy using a multidimensional screening strategy
Blood·2025
Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study
Blood·2025
A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study
Blood·2025Open Access
Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas
Blood·2025Open Access
Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells
Blood·2025Open Access
Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis
Blood·2025
A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study
Blood·2025Open Access
Title first‑in‑human Phase 1 dose‑finding study (VIPER 101) of dual‑population autologous CD5‑deleted anti-CD5 CAR‑T (Senza5 CART5) cells in Relapsed/Refractory T‑cell lymphomas
Blood·2025Open Access
Trends in muscle and fat metrics and their association with outcomes following CAR T-cell therapy in older adults with non Hodgkin lymphoma.
Blood·2025Open Access
Survival outcomes for newly diagnosed non-germinal center large B cell lymphoma patients treated with R-CHOP based on double expressor status and genomic features
Blood·2025Open Access
Fried's frailty phenotype predicts survival in pts with relapsed/refractory lymphoma or myeloma undergoing chimeric antigen receptor T-cell therapy – a prospective, observational Study
Blood·2025Open Access
page 1 of 19Next →

Frequent Co-authors

Stephen J. Schuster(30), Jakub Svoboda(29), Daniel J. Landsburg(21), Elise A. Chong(16), David L. Porter(13), Carl H. June(12), Edward A. Stadtmauer(12), Anthony R. Mato(11), Noelle V. Frey(11), Alison W. Loren(10), Marco Ruella(8), Bruce L. Levine(7), Simon F. Lacey(7), Donald E. Tsai(7), Elizabeth O. Hexner(7), David Porter(7), James N. Gerson(6), Selina M. Luger(6), Dan T. Vogl(6), Stefan K. Barta(6)